Hycanthone

Last updated
Hycanthone
Hycanthone.png
Clinical data
ATC code
  • none
Identifiers
  • 1-(2-Diethylaminoethylamino)-4-(hydroxymethyl)-9-thioxanthenone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.019.512 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C20H24N2O2S
Molar mass 356.48 g·mol−1
3D model (JSmol)
  • CCN(CC)CCNC1=C2C(=C(C=C1)CO)SC3=CC=CC=C3C2=O
  • InChI=1S/C20H24N2O2S/c1-3-22(4-2)12-11-21-16-10-9-14(13-23)20-18(16)19(24)15-7-5-6-8-17(15)25-20/h5-10,21,23H,3-4,11-13H2,1-2H3 X mark.svgN
  • Key:MFZWMTSUNYWVBU-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Hycanthone is the schistosomicide approved by the FDA in 1975. It is a metabolite of lucanthone. Hycanthone interferes with parasite nerve function, resulting in paralysis and death. This agent also intercalates into DNA and inhibits RNA synthesis in vitro and shows potential antineoplastic activity. [1]

Contents

Anti-schistosomal activity

Hycanthone is shown to be an effective inhibitor of acetylcholinesterase (AChE) from Schistosoma mansoni , but is less potential against AChE from mammalian origin. This might come from differences in the configuration of active center between schistosome and mammalian AChE enzymes. [2]

Hycanthone is shown to intercalate into DNA and inhibit RNA synthesis in vitro . A growing body of evidence has shown that hycathone has an antineoplastic activity.[ citation needed ]

Toxicity

Hycanthone is a dose-dependent hepatotoxin, [3] causing hepatocellular injury. [4]

Clinical trials

Physical properties

Physical state Solid
Solubility Soluble in ethanol, methanol, DMSO, and water
Absorption maximum 233, 258, 329, 438 nm
Melting point 173-176 °C
logP 3.74

References

  1. ↑ "hycanthone". NCI Cancer Dictionary.
  2. ↑ Hillman GR, Senft AW (September 1975). "Anticholinergic properties of the antischistosomal drug hycanthone". The American Journal of Tropical Medicine and Hygiene. 24 (5): 827–34. doi:10.4269/ajtmh.1975.24.827. PMID   1190369.
  3. ↑ Teoh NC, Chitturi S, Farrell GC (2010). "Chapter 86: Liver Disease Caused by Drugs". In Feldman M, Friedman LS, Brandt LJ (eds.). Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Vol. 2 (Ninth ed.). Saunders Elsevier. pp. 1413–1446. doi:10.1016/B978-1-4160-6189-2.00086-X. ISBN   978-1-4160-6189-2.
  4. ↑ Stine JG, Lewis JH (2013). "Hepatotoxicity of Antibiotics: A Review and Update for the Clinician". Clinics in Liver Disease. 17 (4): 609–642. doi:10.1016/j.cld.2013.07.008. PMID   24099021.
  5. ↑ Schutt AJ, Dalton RJ, Kovach JS, Moertel CG, O'Connell MJ (June 1983). "Phase II study of hycanthone in patients with advanced colorectal carcinoma". Cancer Treatment Reports. 67 (6): 593–4. PMID   6861166.
  6. ↑ "Phase II Chemotherapy with Hycanthone Mesylate and Flagyl for Advanced Malignant Lymphomas". U.S. National Cancer Institute. Archived from the original on 13 February 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.